We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Amgen Gets Mixed Ruling In Patent Fight

Law360 (August 3, 2006, 12:00 AM EDT) -- The U.S. Court of Appeals for the Federal Circuit Thursday issued a mixed ruling in Amgen Inc.’s nearly decade-long legal spat with two pharmaceutical companies over patents related to Amgen’s blockbuster anemia drug Epogen.

A recombinant version of the kidney hormone erythropoietin (EPO), Epogen is used to increase red blood cells in patients with kidney failure and in for patients on dialysis. Its sales were $613 million for the second quarter of 2006.

The case stretches back to April 1997, when Amgen sought declaratory judgment against...
To view the full article, register now.